🔎 Trials Near Me

Почетна › Akutna mijeloidna leukemija › Северна Каролина

Kliničke studije za Akutna mijeloidna leukemija u državi Северна Каролина

46 studija za Akutna mijeloidna leukemija traži učesnike na lokacijama u državi Северна Каролина.

Gradovi u državi Северна Каролина

Zvanični tekst studije (na engleskom)

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Duke University Medical Center, Durham
  • East Carolina University, Greenville
  • и још 1
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06317649

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • University of North Carolina, Chapel Hill, Chapel Hill
  • Duke University Medical Center, Durham
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07007312

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Duke University Medical Center, Durham
  • East Carolina University, Greenville
  • и још 1
Тражи се учесникФаза 2
Узраст од 18 до 59 · Оба пола · Ажурирано 9. 11. 2026. · NCT05554406

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  • US-Charlotte NC-NOVANTCHARLOTTE, Charlotte
  • US-Winston-Salem NC-NOVANTWINSTON, Winston-Salem
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT07223814

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • AdventHealth Infusion Center Asheville, Asheville
  • Southeastern Medical Oncology Center-Clinton, Clinton
  • AdventHealth Infusion Center Haywood, Clyde
  • и још 6
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

  • Atrium Health Wake Forest Baptist Medical Center, Winston-Salem
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07471841

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • Atrium Health, Charlotte
  • Novant Health Charlotte, Charlotte
  • Carolina Oncology Specialists, Charlotte
  • и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06852222

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

  • Wake Forest University Health Sciences, Winston-Salem
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06484062

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Novant Health Presbyterian Medical Center, Charlotte
  • и још 5
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT05564390

A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies

  • Novant Health Cancer Institute, Charlotte
  • Novant Health Cancer Institute, Winston-Salem
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 30. 10. 2026. · NCT06906380

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

  • Duke Cancer Center, Durham
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT05143996

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Novant Health Presbyterian Medical Center, Charlotte
  • Duke University Medical Center, Durham
  • и још 3
Тражи се учесникФаза 2
Узраст од 18 до 59 · Оба пола · Ажурирано 28. 10. 2026. · NCT05554393

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Тражи се учесникОпсервациона студија
Узраст од 18 до 120 · Оба пола · Ажурирано 28. 10. 2026. · NCT01137643

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Duke University Medical Center, Durham
  • East Carolina University, Greenville
  • и још 1
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT06672146

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

  • Research Site, Chapel Hill
  • Research Site, Durham
Тражи се учесникФаза 1/2
Узраст 16 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT07155226

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

  • Clinical Trial Site, Chapel Hill
Тражи се учесникФаза 3
Узраст 12 и старији · Оба пола · Ажурирано 21. 10. 2026. · NCT07211958

A Study of Revumenib and Mezigdomide in People With Leukemia

  • University of North Carolina (Data Collection Only), Chapel Hill
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 20. 10. 2026. · NCT07356154

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

  • University of North Carolina at Chapel Hill, Chapel Hill
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT06846606

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • Duke University Medical Center, Durham
Тражи се учесникФаза 1/2
30 Days · Оба пола · Ажурирано 9. 10. 2026. · NCT04065399

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

  • Novant Health Weisiger Cancer Institute, Charlotte
Тражи се учесникОпсервациона студија
Узраст 0 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT07154823

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • Duke University, Durham
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT04256317

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Mission Hospital, Asheville
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • и још 4
Тражи се учесникФаза 3
6 Months – 21 Years · Оба пола · Ажурирано 17. 9. 2026. · NCT04293562

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  • Novant Health Clinical Research, Charlotte
  • East Carolina University, Greenville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT06824168

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  • UNC School of Medicine, Division of Hematology, Chapel Hill
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 3. 9. 2026. · NCT04588922

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  • US-Chapel Hill-UNCNORTHCAROLINA, Chapel Hill
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 2. 9. 2026. · NCT06652438

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Mission Hospital, Asheville
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • и још 4
Тражи се учесникФаза 1/2
До 22 година · Оба пола · Ажурирано 25. 8. 2026. · NCT04726241

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Wake Forest University Health Sciences, Winston-Salem
Тражи се учесникФаза 1
Узраст од 18 до 75 · Оба пола · Ажурирано 25. 8. 2026. · NCT05886049

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • Atrium Health Levine Cancer Center, Charlotte
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 20. 8. 2026. · NCT06001788

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

  • University of North Carolina at Chapel Hill, Chapel Hill
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 18. 8. 2026. · NCT06656494

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

  • Levine Cancer Institute, Charlotte
  • Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 24. 7. 2026. · NCT06580106

ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia

  • Levine Cancer Insitute, Charlotte
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Тражи се учесник
Узраст од 18 до 64 · Оба пола · Ажурирано 23. 7. 2026. · NCT06945042

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

  • University of North Carolina at Chapel Hill, Chapel Hill
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 10. 7. 2026. · NCT05442216

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

  • University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Section of Hematology/Oncology, Winston-Salem
Тражи се учесник
Узраст 60 и старији · Оба пола · Ажурирано 6. 7. 2026. · NCT06697600

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • University of North Carolina at Chapel Hill, Chapel Hill
  • Levine Children's Hospital, Charlotte
  • Duke University Medical Center, Durham
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 6. 7. 2026. · NCT01351545

Registry of Older Patients With Cancer

  • Seby B. Jones Cancer Center, Boone
  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
  • East Carolina University, Greenville
  • и још 4
Тражи се учесникОпсервациона студија
Узраст 65 и старији · Оба пола · Ажурирано 29. 6. 2026. · NCT01137825

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

  • UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 23. 6. 2026. · NCT05401097

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

  • UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 14. 5. 2026. · NCT06222580

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

  • University of North Carolina, Chapel Hill
Тражи се учесникФаза 1
Узраст 13 и старији · Оба пола · Ажурирано 5. 5. 2026. · NCT04771572

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

  • Wake Forest Baptist Health, Winston-Salem
Тражи се учесникОпсервациона студија
Узраст од 18 до 120 · Оба пола · Ажурирано 13. 4. 2026. · NCT01890486

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  • UNC Hospital, Chapel Hill
  • Duke University, Durham
  • Atrium Wake Forest Baptist Medical Center, Winston-Salem
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 24. 3. 2026. · NCT04988555

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.